{
    "clinical_study": {
        "@rank": "102348", 
        "arm_group": [
            {
                "arm_group_label": "Paricalcitol", 
                "arm_group_type": "Experimental", 
                "description": "Paricalcitol 2 ug/daily for 48 weeks"
            }, 
            {
                "arm_group_label": "Sugar pill", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The main objective of this study is to examine if paricalcitol may reduce progression of\n      graft fibrosis and proteinuria in kidney transplant patients. Cyclosporine and tacrolimus\n      have a detrimental long-term effect by inducing graft fibrosis. About 50% of graft losses\n      are related to interstitial fibrosis. Paricalcitol is a vitamin D receptor activator\n      indicated for treatment of secondary hyperparathyroidism. Paricalcitol is known to exert an\n      anti-inflammatory and antifibrotic and attenuate cyclosporine-induced fibrosis. Paricalcitol\n      is also shown to be renoprotective by reducing proteinuria. No randomized controlled trials\n      with paricalcitol are performed in renal transplant patients examining the effect on\n      proteinuria and graft fibrosis."
        }, 
        "brief_title": "Oral Paricalcitol in Renal Transplant Recipients for Reducing Albuminuria", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Proteinuria", 
        "condition_browse": {
            "mesh_term": [
                "Albuminuria", 
                "Proteinuria"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  kidney transplant patients\n\n        Exclusion Criteria:\n\n          -  Previously transplanted"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 23, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01694160", 
            "org_study_id": "2012/107 D", 
            "secondary_id": "2012-000429-32"
        }, 
        "intervention": [
            {
                "arm_group_label": "Paricalcitol", 
                "intervention_name": "Paricalcitol", 
                "intervention_type": "Drug", 
                "other_name": "Zemplar"
            }, 
            {
                "arm_group_label": "Sugar pill", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ergocalciferols"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "kidney transplant patients", 
            "Albuminuria"
        ], 
        "lastchanged_date": "September 26, 2012", 
        "location": {
            "contact": {
                "email": "hallvard.holdaas@oslo-universitetssykehus.no", 
                "last_name": "Hallvard Holdaas, MD, PhD", 
                "phone": "4723071247"
            }, 
            "facility": {
                "address": {
                    "city": "Oslo", 
                    "country": "Norway", 
                    "zip": "0424"
                }, 
                "name": "Renal Section, Oslo University Hospital, Rikshospitalet"
            }, 
            "investigator": {
                "last_name": "Hallvard Holdaas, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Norway"
        }, 
        "number_of_arms": "2", 
        "official_title": "Consultant in Neprhology. MD. PhD.", 
        "overall_official": {
            "affiliation": "Oslo University Hospital Rikshospitalet", 
            "last_name": "Hallvard Holdaas, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Norway: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Albumin exretion", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01694160"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Oslo University Hospital", 
            "investigator_full_name": "Hallvard Holdaas", 
            "investigator_title": "Consultant Nephrology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Oslo University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Oslo University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}